◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocks0-9 › 6699

Angelalign Technology Inc. (6699) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Medical Instruments & Supplies · DATA UPDATED 2026-08-10

Angelalign Technology Inc. (6699) operates in the Medical Instruments & Supplies industry and is headquartered in Shanghai, China with about 4,312 employees. Its market capitalization is roughly $16 billion. In the fiscal year ended 2025-12-31, 6699 reported $370M in revenue and $28M in net income.

Angelalign Technology Inc., an investment holding company, researches and designs, manufactures, sells, and markets clear aligner treatment solutions in the People's Republic of China and internationally.

Interactive charts & full statements →

6699 Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-31
Total Revenue$370M$269M$210M$184M
Gross Profit$233M$168M$131M$114M
Operating Income (EBIT)$32M($4M)($2M)$26M
Net Income$28M$12M$8M$31M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

6699 Free Cash Flow History

Cash flow2025-12-312024-12-312023-12-312022-12-312021-12-31
Dividends Paid($18M)($24M)($15M)($26M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

6699 Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Assets$764M$678M$672M$644M
Total Liabilities$260M$198M$190M$127M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 6699 viewer.

Other Companies in Medical Instruments & Supplies

← 6698All “0-9” companies6701 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.